Management of hepatic HBV reinfection after liver transplantation
- VernacularTitle:肝移植术后HBV再感染的治疗
- Author:
Guilong DENG
;
Zhihai PENG
;
Junming XU
;
Guoqing CHEN
;
Guoqiang QIU
- Publication Type:Journal Article
- Keywords:
Liver transplantation;
Lamivudine;
Hepatitis B virus immune globulin;
Adefovir dipivoxil;
YMDD mutation
- From:
Chinese Journal of General Surgery
2000;0(11):-
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study the effect of antivirus therapy of HBV reinfection and YMDD mutation after liver transplantation. Methods Fifteen of 317 patients with HBV-related end-stage liver diseases received lamivudine ( LAM ) monothereapy, others received combination low-dose hepatitis B immune globulin( HBIG) and LAM (or adefovir dipivoxil, ADV) therapy, as prophylaxis against HBV reinfection after OLT. Hepatitis serum markers, HBsAg, HBeAg, HBcAb-IgM, and HBcAg were detected every 2 weeks by immunohistochemistry. Serum HBV DNA was examined by PCR every 2 weeks. HBsAg and HBcAg in the liver specimens were examined by immunohistochemistry. YMDD mutation was detected by PCR in those patients with recurrence of positive HBV DNA posttransplantation. Results In LAM monotherapy group, 4 developed HBV reinfection out of 15 patients with pretreatment positve HBV DNA. Sixteen of 302 patients with combination HBIG and LAM therapy suffered from posttransplant HBV reinfection, the difference between the two groups was significant (26.7% vs. 5. 30% ,P
